CompletedNCT00908154
Repeated doses of GSK1014802: safety in people with bipolarity
About this title
Read the official source — NCT00908154Medication studyAges 18–55United Kingdom
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: May 31, 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 51
- Sponsor
- Biogen
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00908154
- Official title
Show the full official title
Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802 and Its Interaction With Food in Healthy Volunteers
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Biogen.
Did this study involve medication?
Yes. The study involved medication, including Placebo and GSK1014802.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
